{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:34:42Z","timestamp":1775039682385,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00432-017-2359-9","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T14:40:46Z","timestamp":1487688046000},"page":"1225-1233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nilotinib first-line therapy in patients with Philadelphia chromosome-negative\/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis"],"prefix":"10.1007","volume":"143","author":[{"given":"Andreas","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u04abois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ljubomir","family":"Petrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J. W. M.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Liz Paciello","family":"Coronel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Asuncion Echeveste","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Garcia-Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Dezzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"2359_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884. doi: 10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"2359_CR2","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.162.6.2175","volume":"162","author":"CR Bartram","year":"1985","unstructured":"Bartram CR (1985) bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia. J Exp Med 162:2175\u20132179","journal-title":"J Exp Med"},{"key":"2359_CR3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","volume":"306","author":"CR Bartram","year":"1983","unstructured":"Bartram CR et al (1983) Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306:277\u2013280","journal-title":"Nature"},{"key":"2359_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-1-4614-6176-0_8","volume":"779","author":"A Bisen","year":"2013","unstructured":"Bisen A, Claxton DF (2013) Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. Adv Exp Med Biol 779:179\u2013196. doi: 10.1007\/978-1-4614-6176-0_8","journal-title":"Adv Exp Med Biol"},{"key":"2359_CR5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/1097-0142(19950115)75:2<464::AID-CNCR2820750209>3.0.CO;2-E","volume":"75","author":"JE Cortes","year":"1995","unstructured":"Cortes JE, Talpaz M, Beran M, O\u2019Brien SM, Rios MB, Stass S, Kantarjian HM (1995) Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer 75:464\u2013470","journal-title":"Cancer"},{"key":"2359_CR6","first-page":"186","volume":"8","author":"NC Cross","year":"1994","unstructured":"Cross NC, Melo JV, Feng L, Goldman JM (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8:186\u2013189","journal-title":"Leukemia"},{"key":"2359_CR7","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, M\u00fcller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26:2172\u20132175. doi: 10.1038\/leu.2012.104","journal-title":"Leukemia"},{"key":"2359_CR8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A Klein de","year":"1982","unstructured":"de Klein A et al (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300:765\u2013767","journal-title":"Nature"},{"key":"2359_CR9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0165-4608(91)90145-K","volume":"57","author":"PH Fitzgerald","year":"1991","unstructured":"Fitzgerald PH, Morris CM (1991) Complex chromosomal translocations in the Philadelphia chromosome leukemias. Serial translocations or a concerted genomic rearrangement? Cancer Genet Cytogenet 57:143\u2013151","journal-title":"Cancer Genet Cytogenet"},{"key":"2359_CR10","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096\u20132102. doi: 10.1038\/leu.2012.85","journal-title":"Leukemia"},{"key":"2359_CR11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0165-4608(85)90086-X","volume":"18","author":"S Heim","year":"1985","unstructured":"Heim S, Billstrom R, Kristoffersson U, Mandahl N, Strombeck B, Mitelman F (1985) Variant Ph translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 18:215\u2013227","journal-title":"Cancer Genet Cytogenet"},{"key":"2359_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/leu.2015.270","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A et al (2016a) Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 30:57\u201364. doi: 10.1038\/leu.2015.270","journal-title":"Leukemia"},{"key":"2359_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A et al (2016b) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044\u20131054. doi: 10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"2359_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","volume":"20","author":"T Hughes","year":"2006","unstructured":"Hughes T, Branford S (2006) Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 20:29\u201341. doi: 10.1016\/j.blre.2005.01.008","journal-title":"Blood Rev"},{"key":"2359_CR15","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP et al (2014) Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123:1353\u20131360. doi: 10.1182\/blood-2013-06-510396","journal-title":"Blood"},{"key":"2359_CR16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E et al (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494\u2013500. doi: 10.1182\/blood-2013-06-511592","journal-title":"Blood"},{"key":"2359_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/s1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841\u2013851. doi: 10.1016\/s1470-2045(11)70201-7","journal-title":"Lancet Oncol"},{"key":"2359_CR18","first-page":"143","volume":"87","author":"R La Starza","year":"2002","unstructured":"La Starza R et al (2002) Complex variant Philadelphia translocations involving the short arm of chromosome 6 in chronic myeloid leukemia. Haematologica 87:143\u2013147","journal-title":"Haematologica"},{"key":"2359_CR19","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA et al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:2197\u20132203. doi: 10.1038\/leu.2012.134","journal-title":"Leukemia"},{"key":"2359_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/jco.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D et al (2012) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232\u2013238. doi: 10.1200\/jco.2011.38.6565","journal-title":"J Clin Oncol"},{"key":"2359_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood.V78.1.205.205","volume":"78","author":"P Martiat","year":"1991","unstructured":"Martiat P, Michaux JL, Rodhain J (1991) Philadelphia-negative (Ph\u2212) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique. Blood 78:205\u2013211","journal-title":"Blood"},{"key":"2359_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/sj.leu.2404983","volume":"22","author":"MC M\u00fcller","year":"2008","unstructured":"M\u00fcller MC et al (2008) Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 22:96\u2013102. doi: 10.1038\/sj.leu.2404983","journal-title":"Leukemia"},{"key":"2359_CR23","volume-title":"National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: chronic Myelogenous Leukemia, v1.","author":"NCCN","year":"2016","unstructured":"NCCN (2016) National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: chronic Myelogenous Leukemia, v1., National Comprehensive Cancer Network, Fort Washington"},{"key":"2359_CR24","volume-title":"National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0","author":"NCI-CTCAE","year":"2009","unstructured":"NCI-CTCAE (Version 4.0 2009) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. National Cancer Institute: Bethesda"},{"key":"2359_CR25","first-page":"385","volume":"6","author":"H Nishigaki","year":"1992","unstructured":"Nishigaki H, Misawa S, Inazawa J, Abe T (1992) Absence in Ph-negative. M-BCR rearrangement-positive chronic myelogenous leukemia of linkage between 5\u2032 ABL 3\u2032 M-BCR sequences in Philadelphia translocation. Leukemia 6:385\u2013392","journal-title":"Leukemia"},{"key":"2359_CR26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2013293","journal-title":"Nature"},{"key":"2359_CR27","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259. doi: 10.1056\/NEJMoa0912614","journal-title":"N Engl J Med"},{"key":"2359_CR28","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1023\/A:1008349405763","volume":"10","author":"D Seong","year":"1999","unstructured":"Seong D et al (1999) Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization. Ann Oncol 10:955\u2013959","journal-title":"Ann Oncol"},{"key":"2359_CR29","first-page":"35","volume":"85","author":"M Sessarego","year":"2000","unstructured":"Sessarego M, Fugazza G, Bruzzone R, Ballestrero A, Miglino M, Bacigalupo A (2000) Complex chromosome rearrangements may locate the bcr\/abl fusion gene sites other than 22q11. Haematologica 85:35\u201339","journal-title":"Haematologica"},{"key":"2359_CR30","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.V69.3.971.971","volume":"69","author":"E Shtivelman","year":"1987","unstructured":"Shtivelman E et al (1987) bcr-abl RNA in patients with chronic myelogenous leukemia. Blood 69:971\u2013973","journal-title":"Blood"},{"key":"2359_CR31","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL et al (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30:1648\u20131671. doi: 10.1038\/leu.2016.104","journal-title":"Leukemia"},{"key":"2359_CR32","volume-title":"Tasigna [package insert]","author":"Tasigna","year":"2015","unstructured":"Tasigna (2015) Tasigna [package insert]. Novartis Pharmaceuticals Corporation, East Hanover"},{"key":"2359_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.cancergencyto.2005.11.008","volume":"166","author":"B Todoric-Zivanovic","year":"2006","unstructured":"Todoric-Zivanovic B et al (2006) A Ph-negative chronic myeloid leukemia with a complex BCR\/ABL rearrangement and a t(6;9)(p21;q34.1). Cancer Genet Cytogenet 166:180\u2013185. doi: 10.1016\/j.cancergencyto.2005.11.008","journal-title":"Cancer Genet Cytogenet"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2359-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2359-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2359-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T19:59:37Z","timestamp":1601668777000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2359-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["2359"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2359-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]}}}